FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
38.000,97 +225,59 (+0,60%) Nasdaq
15.387,58 -213,92 (-1,37%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,53 +0,80 (+0,97%) Bitcoin EUR
60.291,51 +694,20 (+1,16%)
Aclaris Therapeutics, Inc. (0H8T.L)
| Chiusura precedente | 1,2500 |
| Aperto | 1,2320 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 1,2250 - 1,2500 |
| Intervallo di 52 settimane | 0,6052 - 10,8700 |
| Volume | |
| Media Volume | 12.279 |
| Capitalizzazione | 359.686 |
| Beta (5 anni mensile) | 0,23 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,3600 |
| Prossima data utili | 06 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic dermatitis. Aclaris anticipates releasi
- GlobeNewswire
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY. A webcast of the fireside chat may be accessed through the “Events” page of t
- GlobeNewswire
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive results from ATI-2138-PKPD-102, a Phase 1 Multiple Ascending Dose (MAD) trial of the investigational compound ATI-2138. Preliminary data from the MA
